Skip to main content
Clinical Trials/NCT04503655
NCT04503655
Completed
Not Applicable

Etude Multicentrique Évaluant L'efficacité D'une Intervention Visant À Réduire La Durée De Séjour Après L'implantation D'une Bioprothèse Aortique Par Voie Transfémorale

University Hospital, Rouen20 sites in 1 country1,842 target enrollmentDecember 16, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Aortic Valve Stenosis
Sponsor
University Hospital, Rouen
Enrollment
1842
Locations
20
Primary Endpoint
To evaluate the effectiveness of a multi-component organizational intervention
Status
Completed
Last Updated
last year

Overview

Brief Summary

Since the first implantation of a percutaneous aortic bioprosthesis (TAVI) in 2002 (Cribier et al. Circulation 2002), TAVI occupies an increasing place in the management of aortic stenosis (AR) . Initially reserved for inoperable patients at high surgical risk, TAVI is also recommended in patients at intermediate risk, especially when a femoral approach (TF) is possible (Baumgartner et al. Eur Heart J. 2017).

Currently, there is no recommendation regarding length of stay after TAVI and practices are extremely heterogeneous. Despite the growing experience of centers, better patient selection and a reduction in complications, the length of stay after TAVI remains very high in France.

Faced with the great disparity observed between the centers, efforts are necessary to educate the centers in order to further reduce the length of stay after TF-TAVI. The aim of the study is to evaluate the effectiveness of an intervention based on training teams to reduce the length of stay after TF-TAVI.

Registry
clinicaltrials.gov
Start Date
December 16, 2020
End Date
February 9, 2022
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University Hospital, Rouen
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient over 18 years of age;
  • Patient hospitalized for TF-TAVI
  • Patient affiliated or benefiting from a health insurance scheme
  • Patient having read and understood the information letter and having signed the consent form.

Exclusion Criteria

  • Proven pregnant woman (positive urine pregnancy test) or breastfeeding or absence of effective contraception (as defined by the WHO) or postmenopausal woman without confirmation diagnosis obtained (amenorrhea not medically induced for at least 12 months before the initiation visit) ; 1
  • Person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curatorship
  • History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participating in the protocol or preventing him from giving his informed consent

Outcomes

Primary Outcomes

To evaluate the effectiveness of a multi-component organizational intervention

Time Frame: Year 1

Proportion of patients benefiting from TF-TAVI with a length of stay less than or equal to 3 days.

Secondary Outcomes

  • To evaluate the implementation of the intervention(Year 1)
  • To identify the factors associated with the effectiveness and safety of the intervention(Year 1)
  • To evaluate the safety of the intervention(Day 30)
  • To evaluate the budgetary impact of the intervention(Year 1)

Study Sites (20)

Loading locations...

Similar Trials